Molecular and cellular basis of restenosis after percutaneous coronary intervention: The intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system

Journal of Pathology

Volumn 203, Issue 4, 2004, Pages 861-870

  Lee, Michael S ^a   David, Eric M ^b   Makkar, Raj R ^a   Wilentz, James R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c College of Physicians and Surgeons ^*  (United States)

Author keywords

In stent restenosis; Leukocytes; Percutaneous coronary intervention; Platelets

Indexed keywords

ABCIXIMAB; ADVANCED GLYCATION END PRODUCT RECEPTOR; CD11B ANTIGEN; CD40 LIGAND; CD63 ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; FIBRINOGEN RECEPTOR; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PHOSPHODIESTERASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN ANTIBODY; RANTES; RECOMBINANT INTERLEUKIN 10; THROMBOCYTE ACTIVATING FACTOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TRAPIDIL; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

ARTERY INTIMA PROLIFERATION; BALLOON DILATATION; BLOOD CLOTTING; CELL INTERACTION; CORONARY STENT; DIABETES MELLITUS; DRUG MECHANISM; FIBRINOLYSIS; HEALING; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; MOLECULAR MECHANICS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RESTENOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD COAGULATION; BLOOD PLATELETS; CORONARY RESTENOSIS; FIBRINOLYSIS; HUMANS; LEUKOCYTES; RECURRENCE;

EID: 4143141069     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1598     Document Type: Review

References (113)

1. Mickelson JK, Lakkis NM, Villareal-Levy G, Hughes BJ, Smith CW. Leukocyte activation and platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? J Am Coll Cardiol 1996; 28: 345-353.
2. Serrano CV, Ramires JAF, Venturinelli M, et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 1997; 29: 1276-1283.
3. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769.
4. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
5. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; 75: 636-642.
6. Fuster V, Falk E, Fallon J, et al. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost 1995; 74: 552-559.
7. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-392.
8. Uchida K, Sasahara M, Morigami N, et al. Expression of platelet derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 1996; 124: 9-23.
9. Bornfeldt KE, Raines EW, Nakano T, et al. Insulin-like growth factor-1 and platelet derived growth factor-BB induce direct migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994; 93: 1266-1274.
10. Tanizawa S, Ueda M, van der Wal AC, Becker AE. Expression of platelet derived growth factor B chain and beta-receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunocytochemical study. Heart 1996; 75: 549-556.
11. Bilder G, Wentz T, Leadley R, et al. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 1999; 99: 3292-3299.
12. Maruyama I, Shigeta K. Regulation of the endothelial function by thrombomodulin and/or thrombin receptor. Rinsho Ketsueki 1994; 35: 234-237.
13. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.
14. Loppnow H, Bil R, Hirt S, et al. Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91: 134-141.
15. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation 1992; 86: III47-III52.
16. Wyble CW, Hynes KL, Kuchibhotla J, et al. TNF-alpha and IL-1 upregulate membrane-bound and soluble E-selectin through a common pathway. J Surg Res 1997; 73: 107-112.
17. Pietersma A, Kofflard M, de Wit LE, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation 1995; 91: 1320-1325.
18. Porreca E, Di Febbo C, Barbacane RC, et al. Effect of interleukin-1 receptor antagonist on vascular smooth muscle cell proliferation. Atherosclerosis 1993; 99: 71 -78.
19. Nikol S, Isner JM, Pickering JG, et al. Expression of transforming growth factor β1 is increased in human vascular restenosis lesions. J Clin Invest 1992; 90: 1582-1592.
20. Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 1998; 137: 267-275.
21. Wahl SM, Allen JB, Weeks BS, Wong HL, Klotman PE. Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci USA 1993; 90: 4577-4581.
22. Simon DI, Rao NK, Xu H, et al. Mae-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
23. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 1999; 138: 968-975.
24. Ward MR, Agrotis A, Kanellakis P, Hall J, Jennings G, Bobik A. Tranilast prevents activation of transforming growth factor-[beta] system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting. Arterioscler Thromb Vasc Biol 2002; 22: 940-948.
25. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-1178.
26. Piek JJ, VanDerWal AC, Meuwissen M, et al. Plaque inflammation in restenotic coronary lesions of patients with stable or unstable angina. J Am Coll Cardiol 2000; 35: 963-967.
27. Ricevuti G, Mazzone A, Pascotti D, De Servi S, Specchia G. Role of granulocytes in endothelial injury in coronary heart disease in humans. Atherosclerosis 1991; 91: 1-14.
28. Bazzoni G, Dejana E, Del Mascio A. Platelet-neutrophil interactions: possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 1991; 76: 491-499.
29. Azar RR, Waters DD. The inflammatory etiology of unstable angina. Am Heart J 1996; 132: 1101-1106.
30. Freuyer DR, Morganroth ML, Todd RF. Surface Mol (CD11b/CD18) glycoprotein is up-modulated by neutrophils recruited to sites of inflammation in vivo. Inflammation 1989; 13: 495-505.
31. Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effects of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-1426.
32. Inoue T, Sohma R, Miyazaki T, Iwasaki Y, Yaguchi I, Morooka S. Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. Am J Cardiol 2000; 86: 1057-1062.
33. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10 134-10 139.
34. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Biol 1997; 17: 528-535.
35. Rollins BJ. Chemokines. Blood 1997; 90: 909-928.
36. Furukawa Y, Matsumori A, Ohashi N, et al. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999; 84: 306-314.
37. Cipollone F, Marini M, Fazia M, et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 2001; 21: 327-334.
38. Oshima S, Ogawa H, Hokimoto S, et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J 2001; 65: 261-264.
39. Roque M, Kim W, Malik A, et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 1997; 17: 417-422.
40. Poon M, Cohen J, Siddiqui Z, Fallon JT, Taubman MB. Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Lab Invest 1999; 79: 1369-1375.
41. Maresta A, Balducelli M, Cantini L, et al. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 1994; 90: 2710-2715.
42. Galassi AR, Tamburino C, Nicosia A, et al. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation. Catheter Cardiovasc Interv 1999; 46: 162-168.
43. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
44. Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol Lett 1994; 45: 61-65.
45. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995; 25: 1129-1132.
46. Selzman CH, Meldrum DR, Cain BS, et al. Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J Surg Res 1998; 80: 352-356.
47. Feldman LJ, Aguirre L, Ziol M, et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 2000; 101: 908-916.
48. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
49. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990; 82: 2190-2200.
50. Saksela O, Rifkin D. Cell-associated plasminogen activation: regulation and physiological function. Anna Rev Cell Biol 1988; 4: 93-126.
51. Noda H, Fuji S, Sobel B. Induction of vascular SMC expression of PAI-1 by thrombin. Circ Res 1993; 72: 36-43.
52. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-9427.
53. Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation 1991; 83: 645-651.
54. Prisco D, Fedi S, Antonucci E, et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001; 104: 181-186.
55. Sakata K, Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
56. Edgington TS, Mackman N, Brand K, et al. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 8: 67-79.
57. Randolph GJ, Luther T, Albrecht S, et al. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 1998; 92: 4167-4177.
58. Mizuno O, Hojo Y, Ikeda U, et al. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000; 85: 154-160.
59. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-392.
60. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/Factor VIIa complex. Thromb Haemost 1997; 78: 1138-1141.
61. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997; 96: 646-652.
62. x, and sulfated glycans modulate this binding. Biochem Biophys Res Commun 1991; 181: 1223-1230.
63. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-554.
64. Palabrica T, Lobb R, Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 1992; 359: 848-851.
65. Inoue T, Hoshi K, Fujito T, Sakai Y, Morooka S, Sohma R. Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 1996; 7: 529-534.
66. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Changes inmembrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996; 76: 166-172.
67. Hayashi S, Watanabe N, Nakazawa K, et al. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 2000; 102: 1710-1717.
68. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, Lincoff AM. Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol 2001; 38: 577-582.
69. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002; 106: 1523-1529.
70. Nieuwenhuis HK, van Oosterhout JJG, Rozenmuller E, van Iwaarden F, Sixma JJ. Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood 1987; 70: 838-845.
71. Tschoepe D, Schultheib HP, Kolarov P, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
72. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-843.
73. Markovitz JH, Roubin GS, Parks JM, Bittner V. Platelet activation and restenosis after coronary stenting: flow cytometric detection of wound-induced platelet activation. Coron Art Dis 1996; 7: 657-665.
74. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
75. Topol EJ, Califf RM, Weisman HF, et al, on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886.
76. Lincoff AM, Califf RM, Moliterno DJ, et al, for the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999; 341: 319-327.
77. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 922-928.
78. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation 1999; 100: 799-806.
79. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-921.
80. Henn V, Slupsky J, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
81. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-620.
82. Urbich C, Dernbach E, Aicher A, et al. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106: 981-986.
83. Weyrich AS, Prescott SM, Zimmerman GA. Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. Circulation 2002; 106: 1433-1435.
84. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-1534.
85. Stouffer GA, Hu Z, Sajid M, et al. β3-integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 1998; 97: 907-915.
86. Coleman K, Branden G, Willingham M, et al. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor αvβ 3, reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 1999; 84: 1268-1276.
87. Slepian MJ, Massia SP, Dehdashti B, et al. β3-integrins rather than β1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration. Circulation 1998; 97: 1818-1827.
88. Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-155.
89. Weerasinghe D, McHugh KP, Ross FP, et al. A role for the αvβ3 integrin in the transmigration of monocytes. J Cell Biol 1998; 142: 595-607.
90. Bishop GG, McPherson JA, Sanders JM, et al. Selective αvβ3-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 2001; 103: 1906-1911.
91. Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (αvβ 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res 1999; 84: 1268-1276.
92. Srivatsa SS, Fitzpatrick LA, Tsao PW, et al. Selective αvβ3 integrin blockade potentially limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointimal formation. Cardiovasc Res 1997; 36: 408-428.
93. Corjay MH, Diamond SM, Schlingmann KL, Gibbs SK, Stoltenborg JK, Racanelli AL. αvβ3, αvβ5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointimal formation. J Cell Biochem 1999; 75: 492-504.
94. Zimmerman GA, McIntyre TM, Prescott SM. Adhesion and signaling in vascular cell-cell interactions. J Clin Invest 1996; 98: 1699-1702.
95. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointimal formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-2500.
96. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. J Am Med Assoc 1997; 277: 715-721.
97. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 1991; 17: 2B-13B.
98. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-225.
99. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanism promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-535.
100. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 2001; 104: 815-819.
101. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
102. Ceriello A, Giugliano D, Quatraro A, et al. Blood glucose may condition Factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-891.
103. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928.
104. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
105. Nishimoto Y, Miyazaki Y, Toki Y, et al. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol 1998; 32: 1624-1629.
106. Nordt TK, Sawa H, Fujii S, et al. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 1998; 30: 1535-1543.
107. Falk E, Shah PK, Faster V. Coronary plaque disruption. Circulation 1995; 92: 657-661.
108. Ishii M, Kameyama M, Inokuchi Y, et al. Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics. Diabetes Res Clin Pract 1987; 1: 45-50.
109. Banskota NK, Taub R, Zellner K, King GL. Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 1989; 3: 1183-1190.
110. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000; 49: 633-639.
111. Law R, Meehan W, Xi X, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-1905.
112. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 2000; 36: 1529-1535.
113. Velazquez EM, Mendoa SG, Wan P, et al. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46: 454-457.